Defy Medical presents menopause care within a broader hormone-therapy practice. That creates a reading problem for anyone searching specifically for micronized progesterone: a page may list several hormones and several ways of administering treatment without connecting every hormone to every route. A nearby mention of capsules does not, by itself, establish a named progesterone capsule.
We reviewed Defy’s menopause, hormone-treatment and cost information on September 29, 2026. The published material supports a consultation-based service. This review asks which details would turn its general menu into a sufficiently specific medicine description, while keeping its spending averages separate from a quote. We have not verified a prescription, pharmacy stock, appointment outcome or individual eligibility.
Read this article by section
The menopause service is more specific than a wellness article
Defy’s menopause service page describes evaluation and treatment through the practice. That is evidence of an actual clinical offer, rather than merely general education about symptoms. It still does not mean that booking results in progesterone treatment. The assessment must establish the reason for considering any medicine and the responsibilities for later review. Defy belongs in this directory as a care provider, with the preparation unresolved. For comparison, Thrivelab’s published pathway expressly describes compounding. The difference is useful when reading the offer, but does not establish which service is clinically preferable or suitable for a particular history.
Do not multiply the hormones by every route on the page
The wider hormone-therapy page discusses several hormones and delivery options. It would be an unsupported step to turn that general discussion into a catalog in which every route is available for progesterone. An oral capsule, a topical preparation and another hormone’s injection are different product propositions. The oral, vaginal and topical guide helps separate those categories before comparing them. A reader can ask Defy to name the route associated with the proposed progesterone prescription, rather than asking whether it offers capsules in general. That wording avoids treating the layout of a marketing page as a dispensing record.
Bioidentical does not distinguish an approved medicine from a compound
Defy uses bioidentical language in its hormone-service description. Chemical identity and product approval answer different questions. FDA’s compounding explanation says compounded drugs are not FDA approved, while the separate Prometrium label describes an approved oral progesterone preparation. These facts do not establish that Defy will prescribe either category to a particular patient. They show why the word bioidentical alone cannot settle it. The approval guide follows that distinction without treating all hormone preparations as interchangeable. Request the actual medicine name and approval category before applying evidence from one product to another.
Micronized needs a formulation around it
The exact Prometrium labeling relates micronization to the oral formulation’s bioavailability and also says absolute oral bioavailability is unknown. That is a qualified statement about the labeled medicine, not proof that every product marketed with the same processing term behaves identically. Defy’s general service pages do not supply the particle characteristics or finished formulation for a particular proposed prescription. The meaning of micronized is therefore only the start of the inquiry. A product name, route and manufacturer or compounding pharmacy are still needed. Nothing in this comparison provides a basis to alter how an existing medicine is taken.
An annual spending average is not a monthly subscription bill
Defy’s BHRT cost explanation describes average spending below $200 per month during the first year and below $150 afterward, combining consultations, laboratory work and medicines. It also describes paying for services when they are needed. Those averages are not a fixed monthly membership charge, a progesterone-only price or a limit on an individual patient’s bill. A quoted prescription may have different quantities and refill costs, while consultations and tests arrive at different times. Ask for an itemized estimate and the payment or cancellation terms for each booked service. The public average cannot establish insurance reimbursement or the price of an unselected preparation. The estimate also needs a time frame. A first consultation, later review and a pharmacy refill can occur on different dates even when a website expresses their combined expense as a monthly average. It is useful to ask which organization issues each bill and whom to contact if the prescription details or price differ from the estimate. That question does not assume that a particular follow-up schedule is clinically required; it identifies who is responsible for explaining the selected arrangement.
The comparison with a membership network is about purchasing structure
Our BodyLogicMD review examines a membership with member pricing for additional services. Defy’s cost page instead presents an average across separately needed items. Comparing the headline figures directly would combine unlike units. The useful comparison is whether the written estimate identifies clinical time, testing, the medicine and later reassessment separately. A network name or an online model does not determine those answers. Readers should also establish which professional handles a question about the prescribed product after the initial appointment, particularly if the dispensing pharmacy is a separate organization. Neither billing model proves better monitoring or better outcomes.
Ask for an identifiable prescription, not a longer hormone list
The strongest next question is a narrow one: if Defy recommends progesterone, what exact preparation is proposed, and what document explains its route, ingredients, intended use and refill terms? Its clinical service provides a place for that discussion; the website menu cannot complete it in advance. FDA’s generic-drug explanation also shows that approved generic status involves defined requirements, not merely sharing an active hormone name. A clinician can explain the rationale and the pharmacist can identify what is supplied. Until those records exist, this remains a review of Defy’s care and purchasing descriptions, with no verified micronized product catalog.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Defy Medical: Menopause careProvider menopause consultation and follow-up offer; no confirmed individual medicine, outcome or availability · Checked 2026-09-29
- Defy Medical: Hormone therapyProvider treatment and route menu; oral hormone capsules do not establish a named progesterone formulation · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29
- Defy Medical: How much does BHRT cost?Provider illustrative monthly cost averages, not fixed monthly billing or a capsule quote · Checked 2026-09-29
- FDA: Generic Drugs — Questions & AnswersFDA public generic-drug explanation, updated September 18, 2026; approved-generic requirements and qualified inactive-ingredient differences, not identification or substitution advice for a particular provider prescription · Checked 2026-09-29